A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Antidepressants is the primary treatment for depression, but only less than 50% of the patients get clinical remission. There is no objective markers to select antidepressants for clinical treatment . Clinical choose usually use experience and waste a lot of time, even the patients cannot be treated timely and effectively. The investigators found that the later antidepressant effect for 8 weeks is related with early brain functional response. Present prospectively drug treatment and follow-up study intends to adopt pharmacological imaging research methods to detect the brain function or structure change of three different mechanisms of antidepressant drugs, selective serotonin reuptake inhibitors (SSRIs, escitalopram), serotonin and norepinephrine reuptake inhibitors (SNRIs, duloxetine), norepinephrine and dopamine reuptake inhibitors (NDRIs, bupropion) in depression patients. Brain functional or structural magnetic resonance imaging data were collected at baseline, 1 days, 14 days and 12 weeks after treatment. The investigators want to observe the changes of brain functional networks and structure at different time points, acute and chronic treatment induced during drug treatment. Combined with the blood concentration detection, symptom change, cognitive function tests, the investigators also hope to determine the different mechanisms of drug efficacy of antidepressants with different mechanisms. The second aim is to explore different mechanisms of brain function for effective or ineffective drug response. The results of the study will help to further explain the mechanism of different antidepressants, to facilitate the development of early indicators for drug efficacy and individual treatment decision.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Eealy Improvement Predicts Antidepressants Response in Adults With Major Depression Disorder

NCT03230682

Major Depressive Disorder

UNKNOWN

Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis

NCT02330679

Major Depressive Disorder

UNKNOWN PHASE4

Major Depressive Disorder In The Elderly

NCT00093288

Depressive Disorder, Major

COMPLETED PHASE3

Lifestyle Interventions to Prevent Cognitive Deficits in Subjects With Depressive Symptoms: From Mechanisms to Clinical Practice

NCT07009223

Major Depressive Disorder (MDD) Physical Activity Inflammation +3 more

NOT_YET_RECRUITING NA

Study Of 323U66 SR In Major Depressive Disorder

NCT00135512

Depressive Disorder

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

about 150 depression patients were divided into three subgroups, for each group was treated by one antidepressant eg.escitalopram,duloxetine,bupropion.Brain magnetic resonance imaging data were conducted for all patients at baseline, 1 days, 14 days and 12 weeks after treatment. The blood concentration detection, symptom change, cognitive function tests were also conducted. combined with these results the investigators aim to determine the different mechanisms of drug efficacy of antidepressants with different mechanisms and to explore different mechanisms of brain function for effective or ineffective drug response

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder Depression, Unipolar

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Escitalopram group

including 50 patients, dosage:start 10mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 20mg/day and last to the end of 12 week. but if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week.

Group Type EXPERIMENTAL

Escitalopram

Intervention Type DRUG

participants take escitalopram tablets based on their severity of depression (10-20mg/day) at least for 12 weeks.

Duloxetine group

including 50 patients, dosage:start 30mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 60mg/day and last to the end of 12 week. but if the reduction rate of HAMD more than 20% relative to baseline,the investigators will continue to use current dosage until the end of 12 week.

Group Type EXPERIMENTAL

Duloxetine

Intervention Type DRUG

participants take Duloxetine capsule based on their severity of depression (60mg/day) at least for 12 weeks.

Bupropion group

including 50 patients, dosage:start 75mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week.if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 150mg/day and last 2 weeks, the investigators assess the HAMD score again, if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week, but if the reduction rate of HAMD still less than 20% relative to baseline, the participants would withdraw.

Group Type EXPERIMENTAL

Bupropion

Intervention Type DRUG

participants take Bupropion tablets based on their severity of depression (75-300mg/day) at least for 12 weeks.

Healthy control

50 age-, gender-,education level- and handedness matched healthy control would recruit by an advertisement in the local community and school, and excluding ① with a severe physical disease and/or neurological disease, ②with substance abuse, ③ with a history of brain injury, ④ inability to undergo a MRI scan.

Group Type PLACEBO_COMPARATOR

Healthy control

Intervention Type OTHER

Healthy control take placebo tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Escitalopram

participants take escitalopram tablets based on their severity of depression (10-20mg/day) at least for 12 weeks.

Intervention Type DRUG

Duloxetine

participants take Duloxetine capsule based on their severity of depression (60mg/day) at least for 12 weeks.

Intervention Type DRUG

Bupropion

participants take Bupropion tablets based on their severity of depression (75-300mg/day) at least for 12 weeks.

Intervention Type DRUG

Healthy control

Healthy control take placebo tablets

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lexapro cymbalta bupropion hydrochloride tablets placebo tablets

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnostic and Statistical Manual (DSM)-IV Major Depression or Dysthymia
* Age 18-60
* Physically healthy
* The score of Hamilton Depression Rating Scale (HAMD)≥18 points
* Drug-free

Exclusion Criteria

* Body metal (e.g., wire stitches, screws in bones, stainless steel hips)
* History of Psychosis or Epilepsy
* Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)
* Bipolar I
* Need for wash-out from effective treatment in order to participate
* Pregnant or breastfeeding
* High suicide risk
* Currently taking (within 2 weeks; 4 weeks for Fluoxetine) antidepressants
* have received regular treatment of electric convulsions, repetitive transcranial magnetic stimulation (rTMS), or systematic psychotherapy within three months

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes